Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism

References

• Choi JS, Choi DH. 2013. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Die Pharmazie. 68:882–888.
   PubMed Web of Science ®Google Scholar
• Cui G, Qin X, Zhang Y, Gong Z, Ge B, Zang YQ. 2009. Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J Biol Chem. 284:28420–28429.
   PubMed Web of Science ®Google Scholar
• Gouws C, Steyn D, Du Plessis L, Steenekamp J, Hamman JH. 2012. Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. Expert Opin Drug Metab Toxicol. 8:973–984.
   PubMed Web of Science ®Google Scholar
• Joyce H, McCann A, Clynes M, Larkin A. 2015. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol. 11:795–809.
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 101:289–294.
   PubMed Web of Science ®Google Scholar
• Klishadi MS, Zarei F, Hejazian SH, Moradi A, Hemati M, Safari F. 2015. Losartan protects the heart against ischemia reperfusion injury: sirtuin3 involvement. J Pharm Pharm Sci: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 18:112–123.
   Google Scholar
• Lehmann K. 2013. Drug interactions—principles, examples and clinical consequences. Additional important drug interactions. Dtsch Arztebl Int. 110:133.
   PubMed Web of Science ®Google Scholar
• Li AP. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today. 6:357–366.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang K, Zheng J, Cheung FS, Chan T, Zhu L, Zhou F. 2014. Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic human solute carrier transporters. Pharm Biol. 52:1510–1517.
   PubMed Web of Science ®Google Scholar
• Nguyen MA, Staubach P, Wolffram S, Langguth P. 2014. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – implications for the evaluation of transporter-mediated flavonoid–drug interactions. Eur J Pharm Sci. 61:54–60.
   PubMed Web of Science ®Google Scholar
• Orvos P, Virag L, Talosi L, Hajdu Z, Csupor D, Jedlinszki N, Szel T, Varro A, Hohmann J. 2015. Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential – a safety approach. Fitoterapia. 100:156–165.
   PubMed Web of Science ®Google Scholar
• Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ, Tong XL. 2015. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol. 2015:905749.
   PubMed Web of Science ®Google Scholar
• Park SH, Sung JH, Kim EJ, Chung N. 2015. Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines. Braz J Med Biol Res. 48:111–119.
   PubMed Web of Science ®Google Scholar
• Qi X, Qin J, Ma N, Chou X, Wu Z. 2014. Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation. Int J Pharm. 472:40–47.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
   PubMed Web of Science ®Google Scholar
• Rincon J, Correia D, Arcaya JL, Finol E, Fernandez A, Perez M, Yaguas K, Talavera E, Chavez M, Summer R, et al. 2015. Role of angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life Sci. 124:81–90.
   PubMed Web of Science ®Google Scholar
• Shen N, Huan Y, Shen ZF. 2012. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol. 694:120–126.
   PubMed Web of Science ®Google Scholar
• Soldner A, Benet LZ, Mutschler E, Christians U. 2000. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 129:1235–1243.
   PubMed Web of Science ®Google Scholar
• Varshney E, Saha N, Tandon M, Shrivastava V, Ali S. 2013. Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region. Eur J Drug Metab Pharmacokinet. 38:275–282.
   PubMed Web of Science ®Google Scholar
• Wen F, Shi M, Bian J, Zhang H, Gui C. 2016. Identification of natural products as modulators of OATP2B1 using LC–MS/MS to quantify OATP-mediated uptake. Pharm Biol. 54:293–302.
   Google Scholar
• Wrighton SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 22:1–21.
   PubMed Web of Science ®Google Scholar
• Xiaoyang L, Chenming N, Chengqing L, Tao L. 2015. Drug–drug interaction prediction between ketoconazole and anti-liver cancer drug Gomisin G. Afr Health Sci. 15:590–593.
   PubMed Web of Science ®Google Scholar
• Yang SH, Cho YA, Choi JS. 2011. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin. 32:967–972.
   PubMed Web of Science ®Google Scholar
• Yang SH, Choi JS, Choi DH. 2011. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology. 88:1–9.
   PubMed Web of Science ®Google Scholar
• Yasar U, Babaoglu MO, Bozkurt A. 2008. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol. 103:176–179.
   PubMed Web of Science ®Google Scholar
• Ye L, Wang T, Tang L, Liu W, Yang Z, Zhou J, Zheng Z, Cai Z, Hu M, Liu Z. 2011. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci. 100:5007–5017.
   PubMed Web of Science ®Google Scholar
• Yoshitani T, Yagi H, Inotsume N, Yasuhara M. 2002. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 25:1077–1083.
   PubMed Web of Science ®Google Scholar
• Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. 1995. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos. 23:285–289.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, et al. 2007. Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci. 10:496–503.
   PubMed Web of Science ®Google Scholar
• Zhang X, Qiu F, Jiang J, Gao C, Tan Y. 2011. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica. 41:290–296.
   PubMed Web of Science ®Google Scholar